Healthcare Triangle Signs Letter of Intent to Pursue the Proposed Acquisition of Roboticom's Cutting-Edge Industrial Precision Robotics Automation Business
Rhea-AI Summary
Healthcare Triangle (HCTI) signed a non-binding Letter of Intent on September 23, 2026 to acquire Roboticom’s industrial precision robotics automation business from Crestpoint Capital for total consideration of up to $30 million in cash and equity paid over time.
The proposed deal covers 100% of Roboticom customer contracts, specified intellectual property, trademarks and related business assets. Roboticom, based in Pisa, Italy, sells SandRob™, ORTIS™ and ScultoRob™ systems for precision surface treatment across aerospace, marine, composites, orthotics and prosthetics, automotive, advanced manufacturing and industrial tooling sectors.
Based on unaudited data from current owners, Roboticom generated about $14.1 million in revenue, $6.9 million in gross margin and was EBITDA-positive in fiscal 2025. Roboticom management’s unaudited plan targets approximately $153.5 million in revenue and $64 million in adjusted operating contribution by fiscal 2029/30, but these projections are unverified by HCTI, not endorsed by HCTI and subject to significant uncertainty.
Positive
- Roboticom FY 2025 revenue approximately $14.1 million with $6.9 million gross margin and EBITDA-positive performance
- Proposed consideration up to $30 million in cash and equity for 100% of customer contracts, IP, trademarks and business assets
- Five-year management plan targets about $153.5 million revenue and $64 million adjusted operating contribution by FY 2029/30 (unaudited, unverified)
Negative
- LOI is non-binding, so the proposed acquisition may not be consummated
- Roboticom projections are unaudited, not independently verified or endorsed by HCTI, and subject to significant uncertainty
- Adjusted operating contribution is a non-GAAP metric that is not reconciled to a comparable GAAP measure
Details
Market move: HCTI +177.55% vs previous close. Roboticom acquisition LOI
On Sep 23, the day this news came out, the latest delayed price for HCTI is 177.55% above the previous close. Argus tracked a peak move of +150.0% during the session. Our momentum scanner has recorded 45 alerts for this stock so far that day. The latest delayed price is $2.40. Relative volume is exceptionally heavy at 756.1x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Proposed consideration
- Up to $30 million
- Proposed acquisition; cash and equity paid over time
- Assets and contracts to be acquired
- 100%
- Proposed transaction structure
- Revenue
- $14.1 million
- Roboticom fiscal year 2025; unaudited information provided by its current ownership group
- Gross margin
- $6.9 million
- Roboticom fiscal year 2025; unaudited information provided by its current ownership group
- Revenue target
- $153.5 million
- Roboticom management target for fiscal year 2029/30; unaudited and unverified
- Adjusted operating contribution target
- $64 million
- Roboticom management target for fiscal year 2029/30; non-GAAP, unaudited and unverified
Key Terms
letter of intent financial
non-gaap financial measure financial
ebitda financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
The proposed acquisition of Roboticom would expand HCTI into industrial robotics and precision automation; Roboticom management's five-year forward-looking projections target
HCTI believes that, if consummated, the proposed acquisition could potentially extend the Company's technology platform beyond healthcare into industrial automation and advanced manufacturing — sectors the Company believes are experiencing significant growth driven in part by AI adoption — while creating an opportunity to combine HCTI's existing artificial intelligence, cloud and data capabilities with Roboticom's established industrial robotics platform.
Roboticom's technology is marketed through its SandRob™, ORTIS™ and ScultoRob™ product lines and serves applications across aerospace, marine, composites, orthotics and prosthetics, automotive, advanced manufacturing and industrial tooling.
Based on unaudited financial information provided by Roboticom's current ownership group, the business generated approximately
Roboticom management's five-year Growth and Operating Plan, prepared solely by Roboticom management, targets the business to reach approximately
Proposed Transaction Structure
Under the terms outlined in the LOI, HCTI would acquire
Management Comment
"I believe this could represent a significant opportunity for HCTI. I am pleased to explore entering the robotics space and the prospect of combining our AI technology with this business to enhance its competitive positioning." — David Ayanoglou, Chief Financial Officer, Healthcare Triangle, Inc.
About Roboticom
According to publicly available information, Roboticom is a brand of Fabrica Machinale Srl, an Epica International company, based in Navacchio di Cascina (
About Healthcare Triangle, Inc.
Healthcare Triangle, Inc. (Nasdaq: HCTI), based in Pleasanton, California, reinforces healthcare progress through breakthrough technology and extensive industry knowledge and expertise. The Company supports healthcare organizations — including hospitals and health systems, payers, and pharma/life sciences organizations — in their effort to improve health outcomes through better utilization of the data and information technologies they rely on. Healthcare Triangle's Cloud and Data Platform (CaDP), marketed as CloudEz™ and DataEz™, has achieved HITRUST Risk-based, 2-year (r2) Certified status, demonstrating to clients the highest standards for data protection and information security.
Forward-Looking Statements and Safe Harbor Notice
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 concerning the proposed acquisition of intellectual property, trademarks and business assets associated with Roboticom, including statements regarding the anticipated terms, timing, financing and completion of the proposed transaction, Roboticom's historical and projected financial performance, the potential future spin-off or public listing referenced in the LOI, and the anticipated strategic benefits to HCTI. Such forward-looking statements include words such as "proposed," "intend," "anticipate," "target," "believe" and similar expressions. The fiscal year 2025 financial information was provided by Roboticom's current ownership group, and the fiscal year 2029/30 financial projections were prepared solely by Roboticom management; the projections are not adopted or endorsed by HCTI. The financial information is unaudited, and the financial information and projections have not been independently verified by HCTI; they are subject to significant assumptions, risks and uncertainties, and investors should not place undue reliance on the projections. There is no assurance that Roboticom will achieve these historical results on a verified basis or any projected future results, and actual results may differ materially. The LOI is non-binding, and the proposed transaction is subject to significant risks, uncertainties and conditions, including completion of satisfactory due diligence (including confirmation of clear title to the assets to be acquired), completion of an audit of the target's financial statements, HCTI's ability to secure financing, receipt of required approvals, integration risks, compliance with foreign regulatory requirements, and negotiation of definitive agreements. There is no assurance that a definitive agreement will be signed, that the proposed transaction will be completed on the terms described or at all, or that any future spin-off or listing transaction will be pursued or completed. Nothing in this press release constitutes an offer to sell or a solicitation of an offer to buy any securities, nor a representation that Roboticom, the acquired assets, or any successor entity will be listed on Nasdaq, NYSE or any other exchange. Actual results could differ materially from any forward-looking statements as a result of these and other risks, including those described in HCTI's most recent Annual Report on Form 10-K and other filings with the U.S. Securities and Exchange Commission (the "SEC"). The Company's SEC filings are available at www.sec.gov. All forward-looking statements in this press release are qualified by these cautionary statements, and HCTI undertakes no obligation to update any forward-looking statement except as required by law.
Investor Contact
Healthcare Triangle, Inc.
1-800-617-9550
ir@healthcaretriangle.com
View original content:SOURCE Healthcare Triangle, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What business assets of Roboticom would Healthcare Triangle acquire under the LOI?
The LOI outlines that HCTI would acquire 100% of Roboticom’s customer contracts, identified intellectual property, trademarks and related business assets associated with its industrial robotic automation systems.
In which industries does Roboticom currently market its robotics automation systems?
Roboticom markets its SandRob™, ORTIS™ and ScultoRob™ product lines for precision surface treatment in aerospace, marine, composites, orthotics and prosthetics, automotive, advanced manufacturing and industrial tooling applications.
How does Healthcare Triangle describe the strategic rationale for the proposed acquisition?
The company believes the acquisition, if completed, could extend its technology platform beyond healthcare into industrial automation and advanced manufacturing, and create an opportunity to combine HCTI’s AI, cloud and data capabilities with Roboticom’s industrial robotics platform.
What cautions are attached to Roboticom management’s financial projections?
The projections for approximately $153.5 million in revenue and $64 million in adjusted operating contribution by fiscal 2029/30 are unaudited, prepared solely by Roboticom management, have not been independently verified, are not adopted or endorsed by HCTI and are subject to significant assumptions and uncertainties, so actual results may differ materially.
How is the non-GAAP measure "adjusted operating contribution" characterized?
“Adjusted operating contribution” is identified as a non-GAAP financial measure that has not been reconciled to the most directly comparable GAAP measure and may not be comparable to similarly titled measures used by other companies.